近日,博雅生物(300294.SZ)发布公告称,收到控股股东华润医药控股的告知函。华润医药控股于2024年11月8日至2025年2月7日期间,通过深圳证券交易所交易系统以集中竞价交易方式累计增持公司股份510.65万股,占公司总股本的1.0127%。尽管控股股东积极增持,但博雅生物2024年前三季度的业绩表现较为疲软。报告期内,公司实现营业收入12.45亿元,同比下降43.16%;归母净利润为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.